Efficacy of venlafaxine compared with tricyclic antidepressants in depressive disorder: a meta-analysis

Abstract

With respect to the pharmacological characteristic, venlafaxine is comparable with tricyclic antidepressants (TCAs), and venlafaxine might be comparable in efficacy. We performed a systematic review investigating the relative efficacy and tolerability of venlafaxine compared with TCAs (imipramine, clomipramine, amitriptyline, nortriptyline and desipramine). Relevant double-blind randomised trials were identified from systematic searches of electronic databases. An exact analysis of the estimated odds ratios of response of the TCA relative to venlafaxine showed no overall significance of treatment effect (P = 0.38). The odds ratios were not homogenous across studies (P = 0.0213). The average dose of venlafaxine was 103.5 mg/day and for the TCA 106.1 mg/day. An exact analysis of the estimated odds ratios of the withdrawals and side effects in the trials with a TCA relative to venlafaxine showed no overall significance of withdrawal. From our review, no significant difference in treatment effect between low dose of both venlafaxine and the TCAs could be found. In our opinion, because of the heterogeneity of the odds ratios, one cannot conclude that they are of equal efficacy.

Keywords

amitryptiline clomipramine depression imipramine tricyclic antidepressants venlafaxine

References

Abdelmawla AH Langley RW Szabadi E Bradshaw CM (1999) Comparison of the effects of venlafaxine, desipramine, and paroxetine on noradrenaline- and methoxamine-evoked constriction of the dorsal hand vein. Br J Clin Pharmacol 48: 345-354.

Anderson IM (1998) SSRIS versus tricyclic antidepressants in depressed inpatients: a meta-analysis of efficacy and tolerability. Depress Anxiety 7(Suppl. 1): 11-17.

Anderson IM (2000) Selective serotonin reuptake inhibitors versus tricyclic antidepressants: a meta-analysis of efficacy and tolerability. J Affect Disord 58: 19-36.

Benkert O Grunder G Wetzel H Hackett D (1996) A randomized, double-blind comparison of a rapidly escalating dose of venlafaxine and imipramine in inpatients with major depression and melancholia. J Psychiatr Res 30: 441-451.

Birkenhager TK van den Broek WW Moleman P Vulto AG Bruijn JA (2005) Imipramine dose in relation to therapeutic plasma level: are clinical trials using imipramine as a positive control flawed? Psychopharmacology (Berl) 181: 595-599.

Bruijn JA Moleman P Mulder PG van den Broek WW (1999) Depressed in-patients respond differently to imipramine and mirtazapine. Pharmacopsychiatry 32: 87-92.

Deshauer D (2007) Venlafaxine (Effexor): concerns about increased risk of fatal outcomes in overdose. Can Med Assoc J 176: 39-40.

DUAG (1986) Citalopram: clinical effect profile in comparison with clomipramine. A controlled multicenter study. Danish University Antidepressant Group. Psychopharmacology (Berl) 90: 131-138.

DUAG (1990) Paroxetine: a selective serotonin reuptake inhibitor showing better tolerance, but weaker antidepressant effect than clomipramine in a controlled multicenter study. Danish University Antidepressant Group. J Affect Disord 18: 289-299.

10.

Freemantle N Anderson IM Young P (2000) Predictive value of pharmacological activity for the relative efficacy of antidepressant drugs. Meta-regression analysis. Br J Psychiatry 177: 292-302.

11.

Gasto C Navarro V Marcos T Portella MJ Torra M Rodamilans M (2003) Single-blind comparison of venlafaxine and nortriptyline in elderly major depression. J Clin Psychopharmacol 23: 21-26.

12.

Gentil V Kerr-Correa F Moreno R D'Arrigo Busnello E de Campo JA Juruena MF (2000) Double-blind comparison of venlafaxine and amitryptiline in outpatients with major depression with or without melancholia. J Psychopharmacol 14: 61-66.

13.

Glassman AH Perel JM Shostak M Kantor SJ Fleiss JL (1977) Clinical implications of imipramine plasma levels for depressive illness. Arch Gen Psychiatry 34: 197-204.

14.

Harvey AT Rudolph RL Preskorn SH (2000) Evidence of the dual mechanisms of action of venlafaxine. Arch Gen Psychiatry 57: 503-509.

15.

Heninger GR Delgado PL Charney DS (1996) The revised monoamine theory of depression: a modulatory role for monoamines, based on new findings from monoamine depletion experiments in humans. Pharmacopsychiatry 29: 2-11.

16.

Holliday SM Benfield P (1995) Venlafaxine. A review of its pharmacology and therapeutic potential in depression. Drugs 49: 280-294.

17.

Lecrubier Y Bourin M Moon CA Schifano F Blanchard C Danjou P (1997) Efficacy of venlafaxine in depressive illness in general practice. Acta Psychiatr Scand 95: 485-493.

18.

Nelson JC Mazure CM Bowers MB Jatlow PI (1991) A preliminary, open study of the combination of fluoxetine and desipramine for rapid treatment of major depression. Arch Gen Psychiatry 48: 303-307.

19.

Preskorn SH; (1994) Antidepressant drug selection: criteria and options. J Clin Psychiatry 55(Suppl. A): 6-22, discussion 23-24, 98-100.

20.

Samuelian JC Hackett D (1998) A randomized, double-blind, parallel-group comparison of venlafaxine and clomipramine in outpatients with major depression. J Psychopharmacol 12: 273-278.

21.

Sauer H Huppertz-Helmhold S Dierkes W (2003) Efficacy and safety of venlafaxine ER vs. amitriptyline ER in patients with major depression of moderate severity. Pharmacopsychiatry 36: 169-175.

22.

Schweizer E Feighner J Mandos LA Rickels K (1994) Comparison of venlafaxine and imipramine in the acute treatment of major depression in outpatients. J Clin Psychiatry 55: 104-108.

23.

Seth R Jennings AL Bindman J Phillips J Bergmann K (1992) Combination treatment with noradrenalin and serotonin reuptake inhibitors in resistant depression. Br J Psychiatry 161: 562-565.

24.

Shrivastava RK Cohn C Crowder J Davidson J Dunner D Feighner J (1994) Long-term safety and clinical acceptability of venlafaxine and imipramine in outpatients with major depression. J Clin Psychopharmacol 14: 322-329.

25.

Smeraldi E Rizzo F Crespi G (1998) Double-blind, randomized study of venlafaxine, clomipramine and trazodone in geriatric patients with major depression. Primary Care Psychiatry 4: 189-195.

26.

Smith D Dempster C Glanville J Freemantle N Anderson I (2002) Efficacy and tolerability of venlafaxine compared with selective serotonin reuptake inhibitors and other antidepressants: a meta-analysis. Br J Psychiatry 180: 396-404.

27.

Stahl, SM Depression and bipolar disorder. In: SM Stahl (ed), Essential Psychopharmacology. Cambridge: Cambridge University Press.

28.

Stahl SM Entsuah R Rudolph RL (2002) Comparative efficacy between venlafaxine and SSRIs: a pooled analysis of patients with depression. Biol Psychiatry 52: 1166-1174.

29.

Stewart LA Parmar MK (1996) Bias in the analysis and reporting of randomized controlled trials. Int J Technol Assess Health Care 12: 264-275.

30.

Thase ME Entsuah AR Rudolph RL (2001) Remission rates during treatment with venlafaxine or selective serotonin reuptake inhibitors. Br J Psychiatry 178: 234-241.

31.

Thase ME Shelton RC Khan A (2006) Treatment with venlafaxine extended release after SSRI nonresponse or intolerance. J Clin Psychopharmacol 26: 250-258.

32.

Tiihonen J Lönnqvist J Wahlbeck K Klaukka T Tanskanen A Haukka J (2006) Antidepressants and the risk of suicide, attempted suicide, and overall mortality in a nationwide cohort. Arch Gen Psychiatry 63: 1358-1367.

33.

van den Broek WW Birkenhager TK Mulder PG Bruijn JA Moleman P (2004) A double-blind randomized study comparing imipramine with fluvoxamine in depressed inpatients. Psychopharmacology (Berl) 175: 481-486.

34.

Whyte EM Basinski J Farhi P Dew MA Begley A Mulsant BH (2004) Geriatric depression treatment in nonresponders to selective serotonin reuptake inhibitors. J Clin Psychiatry 65: 1634-1641.